Platelet-Leucocyte Aggregates as Novel Biomarkers in Cardiovascular Diseases.
Kinga PlutaKinga PorębskaTomasz Kamil UrbanowiczAleksandra GaseckaAnna Olasinska-WisniewskaRadosław TargońskiAleksandra KrasińskaKrzysztof J FilipiakMarek JemielityZbigniew KrasińskiPublished in: Biology (2022)
Platelet-leucocyte aggregates (PLA) are a formation of leucocytes and platelets bound by specific receptors. They arise in the condition of sheer stress, thrombosis, immune reaction, vessel injury, and the activation of leukocytes or platelets. PLA participate in cardiovascular diseases (CVD). Increased levels of PLA were revealed in acute and chronic coronary syndromes, carotid stenosis cardiovascular risk factors. Due to accessible, available, replicable, quick, and low-cost quantifying using flow cytometry, PLA constitute an ideal biomarker for clinical practice. PLA are promising in early diagnosing and estimating prognosis in patients with acute or chronic coronary syndromes treated by percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). PLA were also a reliable marker of platelet activity for monitoring antiplatelet therapy. PLA consist also targets potential therapies in CVD. All of the above potential clinical applications require further studies to validate methods of assay and proof clinical benefits.
Keyphrases
- percutaneous coronary intervention
- coronary artery bypass grafting
- antiplatelet therapy
- coronary artery disease
- cardiovascular risk factors
- acute coronary syndrome
- st segment elevation myocardial infarction
- acute myocardial infarction
- cardiovascular disease
- st elevation myocardial infarction
- flow cytometry
- low cost
- clinical practice
- type diabetes
- coronary artery
- metabolic syndrome
- cardiovascular events
- atrial fibrillation
- drug induced
- coronary artery bypass
- hepatitis b virus
- peripheral blood
- intensive care unit
- liver failure
- single cell
- pulmonary embolism
- human health
- left ventricular
- aortic valve
- heat stress